Screener
MiniMed Group MMED SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by MiniMed Group in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: MiniMed Group’s 10-Q, filed April 17, 2026.
- Filed
- Apr 17, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-025777
| (in millions, except share and per share data) | Three Months Ended / January 23, 2026 | Three Months Ended / January 24, 2025 | Nine Months Ended / January 23, 2026 | Nine Months Ended / January 24, 2025 |
|---|---|---|---|---|
| Gross Profit | 362 | 395 | 1,200 | 1,123 |
| Operating expenses: | ||||
| Research and development expense | 114 | 112 | 349 | 329 |
| Selling, general, and administrative expense | 309 | 268 | 884 | 804 |
| Certain litigation charges, net | (6) | — | 11 | — |
| Other operating expense (income), net | 45 | (7) | 53 | (12) |
| Operating (loss) profit | (100) | 21 | (97) | 2 |
| Other non-operating (income) expense, net | — | — | — | 1 |
Item 1. Financial Statements (
FAQ
- What is MiniMed Group's SG&A?
- MiniMed Group (MMED) reported SG&A of $309M in Q1 2026.
- How has MiniMed Group's SG&A changed year-over-year?
- MiniMed Group's SG&A increased by 15.3% year-over-year, from $268M to $309M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about MiniMed Group's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude